The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients.

Expert Rev Pharmacoecon Outcomes Res

a 1 Merck Sharp & Dohme, Qta. da Fonte 19, 2770-192 Paço de Arcos, Portugal.

Published: December 2016

AI Article Synopsis

  • Severe hypoglycemia is a serious complication of diabetes that leads to increased healthcare costs and impacts on patient health, which the study aims to measure from a societal perspective.
  • Conducted in Portugal, the study analyzed data from 238 Type-2 diabetes patients to assess healthcare resource use and costs associated with severe hypoglycemic events, including expenses from emergency services and hospital stays.
  • The findings revealed that each hypoglycemic episode costs an average of €1493, with hospitalization costs being significant, highlighting the financial burden these events place on the healthcare system, particularly the National Health Service.

Article Abstract

Introduction: Hypoglycemia is an acute complication of diabetes that increases morbidity, mortality and disease costs. We aim to estimate healthcare resource consumption and costs associated with severe hypoglycemia using the societal perspective.

Methods: A cross-sectional, observational, nationwide, multicenter, hospital-based study was conducted in seven centers of Portuguese mainland with a 1-year enrolment period. Unit costs were extracted from official/public data sources. Patient-level data were used to quantify healthcare resource use related to emergency transportation, emergency-department care and hospitalization. Productivity loss was calculated based on the Human Capital Approach.

Results: The study enrolled 238 Type-2 diabetic patients and the proportion of hypoglycemic episodes among all emergency events during the study period was 0.075% (95% CI: 0.067-0.083%). Mean patient age was 76 years and 57.6% were female. At time of the emergency department admission, 55% of patients were using insulin, 31.5% were being treated with secretagogues, 6.7% were on a combination of both, and 6.7% were on other oral antihyperglycemic agents. Estimated mean costs in the emergency department were: emergency transportation €33, medication €4, laboratory workup €56, other exams €72, physician and nurse time €30 and €13, respectively. Mean hospitalization cost was €1271. Indirect cost averaged €15. Overall cost per hypoglycemic episode averaged €1493 (standard deviation: €2962; range: €34-26,818). Patients treated with secretagogues had the highest rates of hospitalizations and mean costs.

Conclusion: We conclude that severe hypoglycemic events represent a substantial cost for society and in particular for the hospitals of the National Health Service.

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.2015.1084230DOI Listing

Publication Analysis

Top Keywords

severe hypoglycemic
8
hypoglycemic episodes
8
diabetic patients
8
healthcare resource
8
emergency transportation
8
emergency department
8
treated secretagogues
8
cost
5
emergency
5
cost managing
4

Similar Publications

Background: Recent advances in diabetes care and technology, such as real-time continuous glucose monitoring, can help people live more freely, with more flexibility and fewer constraints, thereby enhancing quality of life (QOL). To date, there has been no validated means for measuring this key psychological dimension. We developed the Diabetes Constraints Scale (DCS) to assess perceived constraints pertaining to diabetes self-management.

View Article and Find Full Text PDF

Background: Older adults with type 1 diabetes are at risk for serious hypoglycemia. Automated insulin delivery can reduce risk but has not been sufficiently evaluated in this population.

Methods: We conducted a multicenter, randomized crossover trial in adults older than or equal to 65 years of age with type 1 diabetes.

View Article and Find Full Text PDF

Neonatal diabetes is an infrequent disorder that may present as transient, permanent, or syndromic. It is most commonly caused by pathogenic variants involving the ABCC8, KCNJ11, and INS genes. To describe a neonate with permanent diabetes mellitus due to a previously unreported variant in the INS gene, outlining the diagnostic complexities, therapeutic interventions, and related clinical challenges.

View Article and Find Full Text PDF

Background: Optimizing outcomes of hospitalized patients anchors on standardizing processes in medical management, interventions to reduce the risk of decompensation, and prompt intervention when a patient decompensates.

Methods: A quality improvement initiative (optimized sepsis and respiratory compromise management, reducing health care-associated infection and medication risk, swift management of the deteriorating patient, feedback on performance, and accountability) was implemented in a multistate health system. The primary outcome was risk-adjusted in-hospital mortality.

View Article and Find Full Text PDF

Isoquercitrin improves diabetes nephropathy by inhibiting the sodium-glucose co-transporter-2 pathway.

Biochem Biophys Res Commun

December 2024

Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China; Qingdao Key Laboratory of Thyroid Diseases, Medical Research Cente, Qingdao, China. Electronic address:

Diabetic nephropathy (DN) is one of the most severe kidney complications and the primary contributor to end-stage renal disease on a global scale. It exacerbates the morbidity, mortality, and financial burden for individuals with diabetes. Isoquercitrin, a natural compound found in various plants, has demonstrated potential as an antidiabetic agent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!